Dyne Therapeutics

WALTHAM, MA · Founded 2017 · Biotech · Public

Gene therapy for inherited muscle diseases

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · dyne-tx.com

Sector
Biotech
Headquarters
WALTHAM, MA
Founded
2017
Latest Form D
$116M, Aug 2020
Total capital
$116M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$116M
1 Form D · last Aug 2020
74 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
26
14 pending · first 2024
Rank in peer group#26 of 1449

Capital timeline

2020FEDERAL ↑EQUITY ↓Cumulative $116M1st Form D$116M
2020FEDERAL ↑EQUITY ↓Cumulative $116M1st Form D$116M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$116M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#26 · top 2%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Catherine Stehman-Breen, M.D.DirectorNamed in SEC Form D filings
  • David LubnerDirectorNamed in SEC Form D filings
  • Dirk KerstenDirectorNamed in SEC Form D filings
  • Edward HurwitzDirectorNamed in SEC Form D filings
  • Jason RhodesDirectorNamed in SEC Form D filings
  • Jonathan McNeill, M.D.Executive OfficerNamed in SEC Form D filings
Show all 11 people
  • Joshua BrummExecutive Officer, DirectorNamed in SEC Form D filings
  • Lawrence Klein, Ph.D.DirectorNamed in SEC Form D filings
  • Oxana Beskrovnaya, Ph.D.Executive OfficerNamed in SEC Form D filings
  • Richard ScalzoExecutive OfficerNamed in SEC Form D filings
  • Romesh Subramanian, Ph.D.Executive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 26 granted of 40
Show all 40 patent records
  • Antares TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Caldera TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Ethyreal BioSimilar federal contract value in Biotech · null in contracts
  • Kailera TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Intellia TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Judo BioSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .